In contrast, other study revealed that 5-azacytidine (5-aza-CR)-mediated overexpression of LOXL4 reactivated wild-type p53 and promoted cancer cell death, thus suppressing the development of HCC cancers, which might indicate an improved clinical outcomes of HCC patients (28, 44). Here, LOXL4 is linked to cancer.